From Molecule to Market: Scalable Enteric Solutions for Accelerated Clinical and Commercial Success

As the pharmaceutical industry advances toward more targeted, patient-centric therapies, the need for delivery technologies that bypass the stomach has become critical. Lonza’s Capsugel® Enprotect® capsule represents a breakthrough in enteric technology, offering a bi-layered, ready-to-use solution that protects acid-sensitive APIs without the need for subsequent coating or additional unit operations. This innovation accelerates development timelines and enhances formulation flexibility across a range of modalities, including small molecules, peptides, and live biotherapeutic products. Coupled with Lonza’s Innovaform® Accelerator, Enprotect® capsules can be fully customised to meet molecule and brand requirements, ensuring compatibility and optimised release profiles. This session will explore how Lonza’s products and services enable accelerated, tailored development of oral solid dosage forms, including a full-service pathway from concept-to-patient through Lonza’s cGMP clinical and commercial manufacturing capabilities. Discover how Lonza is redefining what’s possible in oral drug delivery; offering not just a capsule, but a complete solution.